Geneva (ots/PRNewswire) - ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative to tumour biopsy IGNITE supports value of EGFR mutation testing in all patients with advanced NSCLC AstraZeneca today presented results from two key studies showing the effectiveness of plasma circulating tumour DNA (ctDNA) testing for ...
Chicago (ots/PRNewswire) - Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC), demonstrate that the overall disease control rate was 94 percent for patients with EGFR T790M+ tumours - meaning that their ...
London (ots/PRNewswire) - FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) trial to compare fulvestrant to anastrozole (ARIMIDEX(R)) tablets in hormonal therapy-naïve, postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer. ...
London (ots/PRNewswire) - THIS RELEASE IS INTENDED EXCLUSIVELY FOR EUROPEAN MEDIA Data presented today from the VOYAGER study demonstrate the benefits of aggressive statin therapy with CRESTOR(TM) (rosuvastatin) in comparison to atorvastatin and simvastatin in high risk patients. VOYAGER is an individual patient ...
London (ots/PRNewswire) - Results presented from new VOYAGER sub-analysis This release is INTENDED EXCLUSIVELY FOR EUROPEAN media AstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which suggests that achieving an LDL-C goal of 50% reduction in LDL-C levels in patients at high risk requires aggressive ...
London, November 18 (ots/PRNewswire) - AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in ...
Paris (ots/PRNewswire) - - This release is not intended for US media Ticagrelor Recommended for Medically & Invasively Managed NSTE-ACS Patients Regardless of Prior Treatment with Clopidogrel AstraZeneca today announced BRILIQUE (ticagrelor), a new oral antiplatelet medicine, received a Class I recommendation (level ...
Geneva (ots/PRNewswire) - Results from a large pan-European study suggest that up to 135,000 deaths from cardiovascular disease (CVD), such as heart attacks and strokes, could be prevented in Europe each year though better control of risk factors including high blood pressure, high cholesterol, smoking and ...
Prague, November 8 (ots/PRNewswire) - Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year.[i] Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.[ii] The European Study on Cardiovascular Risk Prevention and Management in Daily Practice ...
London (ots/PRNewswire) - A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50% (p=0.028; ...
Milan (ots/PRNewswire) - This press release has been made available on worldwide (excluding US) press communication media for the benefit of correspondents writing for the medical professional press. Differing national legislation, codes of practice, medical practice etc mean that you should contact your local AZ ...
London and San Francisco (ots/PRNewswire) - AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. , significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with methotrexate (MTX), ...
Paris (ots/PRNewswire) - AstraZeneca today announced results from a phase II study evaluating the investigational drug vandetanib for the treatment of patients with locally advanced or metastatic papillary or follicular thyroid cancer. This study, ZACTHYF, showed that treatment with vandetanib significantly ...
Orlando, Florida, November 17 (ots/PRNewswire) - JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular (CV) events in women without established cardiovascular disease (CVD). In this new analysis of 6,801 women from the JUPITER study, rosuvastatin ...
Orlando, Florida, November 17 (ots/PRNewswire) - JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular (CV) events in women without established cardiovascular disease (CVD). In this new analysis of 6,801 women from the JUPITER study, rosuvastatin 20 ...
Barcelona (ots/PRNewswire) - A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death ...
Orlando, Florida (ots/PRNewswire) - Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, ...
Orlando, Florida (ots/PRNewswire) - New data from the AURORA trial, a study in patients with end stage renal disease (ESRD) undergoing chronic haemodialysis, showed that there was no difference between rosuvastatin 10mg and placebo in reducing the combined endpoint of cardiovascular (CV) death, nonfatal stroke, ...
Orlando, Florida (ots/PRNewswire) - Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C ...
Orlando, Florida (ots/PRNewswire) - - A New Analysis From the JUPITER Trial A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol ...
San Diego, California (ots/PRNewswire) - A new analysis from the JUPITER study presented today at the International Stroke Conference (ISC) in San Diego, California, describes details of the stroke data according to gender, ethnicity and baseline risk factors. This data adds to the primary analysis of the JUPITER study which demonstrated that CRESTOR® (rosuvastatin calcium) 20mg significantly reduced the risk of ...
Washington, Dc (ots/PRNewswire) - - International Reach of 'Young Minds in Psychiatry' Awards is Boosted With AstraZeneca Support For the first time, a researcher from China has received one of the American Psychiatric Association's (APA) prestigious "Young Minds in Psychiatry" awards, which were ...
London (ots/PRNewswire) - CRESTOR(TM) (rosuvastatin) is the only statin to show regression of coronary atherosclerosis in a major clinical study. That result, which was based on intravascular ultrasound (IVUS) data from the ASTEROID study, has now been expanded upon by quantitative coronary angiography (QCA) ...
London (ots/PRNewswire) - AstraZeneca (LSE: AZN) (NYSE: AZN) today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare ...
London (ots/PRNewswire) - Data from two observational studies of over 470,000 patients taking statins in routine clinical practice investigating the incidence of cardiovascular events in patients taking CRESTOR(TM) (rosuvastatin) and other statins were presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual ...
Barcelona (ots/PRNewswire) - - For Medical and Healthcare Media Only - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Highlight the Need for More Positive Conversations Through Better Communication, Training and Use of Effective Treatments A devastating moment for a woman undergoing ...
London (ots/PRNewswire) - AstraZeneca today announced enrolment of the first patient in the new GRAVITY study (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY). GRAVITY is a clinical trial examining the impact on LDL-cholesterol ('bad' cholesterol) levels in ...
London (ots/PRNewswire) - - For International Medical Journalists Only AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in ...
Alderley Park, England (ots/PRNewswire) - - FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY - AstraZeneca Collaborates With Myriad Genetics on Phase 2 Trials AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 ...
Alderley Park, England (ots/PRNewswire) - - FOR NON-US/NON-UK MEDICAL MEDIA ONLY ALDERLEY PARK, England, June 4 /PRNewswire/ -- AstraZeneca (LSE: AZN; NYSE: AZN) today announced details of two new investigational cancer therapies at the American Society of Clinical Oncology (ASCO) meeting. AZD2281 (KU-0059436) is a small molecule inhibitor of ...